Kimberly Stegmaier

发表

Abstract IA04: Identification of new vulnerabilities in fusion-driven pediatric cancers with functional and chemical genomic approaches

Kimberly Stegmaier, 2018 .

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies

Pablo Tamayo, Aviad Tsherniak, Ted Liefeld, 2014, Scientific Data.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia

Gabriela Alexe, Tobias Berg, Hanibal Bohnenberger, 2017, Cancer cell.

In Vivo RNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling

Fatima Al-Shahrour, Benjamin L. Ebert, Scott A. Armstrong, 2011 .

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation

Todd R Golub, Kimberly Stegmaier, Andrew L Kung, 2008, Proceedings of the National Academy of Sciences.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing Sarcoma

Todd R Golub, Kimberly Stegmaier, Andrew L Kung, 2007, PLoS medicine.

Proteomic and genetic approaches identify Syk as an AML target.

Tina N. Davis, Steven A Carr, William C Hahn, 2009, Cancer cell.

Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation

Todd R Golub, Brent R Stockwell, Kimberly Stegmaier, 2004, Nature Genetics.

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

Gabriela Alexe, Giovanni Roti, Nicola Tolliday, 2012, The Journal of clinical investigation.

Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.

Giovanni Roti, Lynn VerPlank, Nicola Tolliday, 2013, Chemistry & biology.

In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling.

Fatima Al-Shahrour, Gabriela Alexe, David E Root, 2013, Cancer cell.